---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-26-000042"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2026-08-04T20:03:29+00:00"
generated_at: "2026-08-04T20:05:32.770505+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience Q2 net sales $29.8M, net income $1.0M; launches pharmaceutical program targeting rare diseases

## Summary
- Net sales $29.8M ($24.2M Tru Niagen); gross margin 64.8%; net income $1.0M ($0.01 EPS); adjusted EBITDA $3.0M.
- Launched Niagen Plus telehealth platform with at-home injection kit; received LegitScript certification for advertising.
- Introduced NB4168 for rare genetic diseases targeting Ataxia-Telangiectasia; received FDA Rare Pediatric Disease and EMA Orphan Medicinal Product designations.
- Appointed Abhijit Kale as Senior Director of Global External Research to lead pharmaceutical program.
- 2026 outlook: e-commerce growth 10-15% YoY; ingredient business expected lower; expects increased operating expenses.

## SEC filing metadata
- accession: 0001386570-26-000042
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2026-08-04T20:03:29+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/0001386570-26-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657026000042/cdxc-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-26-000042
- JSON: https://secwatch.observer/filing/0001386570-26-000042.json
- Plain text: https://secwatch.observer/filing/0001386570-26-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.